Ionis Pharmaceuticals, Inc.

IONS: NasdaqGS
34Total

Lowest reading is at 14 out of 100. All scores are out of 100.

About The Company

CEO

Dr. Brett P. Monia Ph.D.

Market Cap

7.40 Billion USD

Sector

Healthcare

Website

https://www.ionis.com

Last Update

27/09/2026, 13:37:05

Description

Ionis Pharmaceuticals, Inc.

Read More

Strongest readings

No reading stands out above its benchmark.

Weakest readings

  • ✘Income is not covering expenditure and investment (free cashflow -3.37 per share)
  • ✘Debt is high at 3.67 times equity
  • ✘Earnings are negative at -0.69 per share
  • ✘The current price sits above estimated fair value (margin of safety -94.05%)
  • ✘Priced well above the cashflow it produces (value score 14 out of 100)

Key Figures

StatusMetricValueReadingMarket avg
Price / earnings (TTM)
N/A19.60x
✘
Margin of safety (DCF)
-94.05%
17.95%
✘
Revenue growth (5y average)
8.88%
10.97%
✘
Dividend yield (TTM)
0.00%
1.85%
✘
Share count, per year
0.77%
0.00%
✘Return on capital employed-3.47%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

14 / 100

Priced above the market on most measures.

StatusMetricValueReadingMarket avg
Price / earnings
N/A19.60x
✘Free cashflow yield-7.58%
4.70%
Price / earnings growthN/A1.50x
Price / book16.82x
—
✘
Margin of safety
-94.05%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 2.65 USD is below the current price of 44.50 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: N/A✘

Current Price: 44.5 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

44 / 100

Growing more slowly than the market on most measures.

StatusMetricValueReadingMarket avg
✘
Revenue growth
8.88%
10.97%
Earnings growthN/A14.48%
Cashflow growthN/A12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Revenue growth has slowed this year (-7.41% against a five year average of 8.88%)

Health

42 / 100

Balance sheet is stretched on several measures.

Measured on Leverage and capital, Funding and liquidity, Earnings quality.

StatusMetricValueReadingThreshold
✘Altman-Z score1.27
3.00
✘Piotroski score3.00
5.00
✘Debt / equity3.67x
0.80x
✔Current ratio7.89x
1.00x
✘Interest coverage-20.11x
2.50x
✔Free cashflow / debt0.34x
0.15x
✔Debt / capital0.79x
1.00x

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Income is not covering expenditure and investment (free cashflow -3.37 per share)

Management

37 / 100

Returns on capital are below the market.

StatusMetricValueReadingMarket avg
✘Return on equity-26.07%
15.00%
✘Return on capital employed-3.47%
10.00%
Return on assets-3.83%
—
Free cashflow return on capital20.51%
—
✘Return on capital, 5y change-2.97%
0.00%
✘
Share count, per year
0.77%
0.00%
✘Share count, recent0.46%
0.00%
Realized buyback returnN/A0.00%
✔Goodwill erosion / equity0.00%
2.00%
Price volatility, 5 year43.96%
—

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✔New shares were issued while the value score was 14 out of 100

Analysts

not enough data
StatusMetricValueReadingNeutral
Analyst opinion scoreN/A50

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Financial History

Annual figures across the full reporting history we hold.

Market Peers

IONS

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

See 35+ Years Annual Reports

Other Information

Company Name

Ionis Pharmaceuticals, Inc.

Currency

USD

Beta

0.419

Vol Avg

3730039

Ceo

Dr. Brett P. Monia Ph.D.

Cik

0000874015

Cusip

Exchange

NasdaqGS

Full Time Employees

1480

Industry

Biotechnology

Sector

Healthcare

Ipo Date

Address

2855 Gazelle Court

City

Carlsbad

State

CA

Country

United States

Zip

92010

Phone

760 931 9200

Analysis Last Updated

27/09/2026, 13:37:05

Financial data compiled from SEC EDGAR filings and Yahoo Finance.

Noticed an error with something on our site?

Data, not advice. Do your own diligence.

We Use Cookies